Myocardial Infarction News and Research

RSS

Medtronic’s Resolute zotarolimus-eluting stent as effective as Xience V everolimus-eluting stent: Study

The highly anticipated first results of the RESOLUTE All Comers study were presented today during the late-breaking clinical trial session of the 2010 EuroPCR meeting. In this novel 2,292-patient randomized trial, the Resolute zotarolimus-eluting stent from Medtronic, Inc. was found to be as safe and effective as the Xience® V everolimus-eluting stent from Abbott Laboratories.

26 May 2010

NEVO Sirolimus-eluting Coronary Stent demonstrates safety and efficacy outcomes at 12 months

At 12 months the NEVO™ Sirolimus-eluting Coronary Stent has continued to demonstrate excellent safety and efficacy outcomes compared to Taxus® Liberte® according to new data presented today from the NEVO™ RES-I clinical trial. These results were presented as a late breaking trial at EuroPCR, the leading medical conference in Europe for physicians specializing in interventional cardiovascular medicine.

26 May 2010

St. Jude Medical initiates enrollment in FAME II trial for coronary artery disease

St. Jude Medical, Inc., a global medical device company, announced today at EuroPCR that the first patient was enrolled in the FAME II (Fractional Flow Reserve (FFR)-Guided Percutaneous Coronary Intervention Plus Optimal Medical Treatment vs. Optimal Medical Treatment Alone in Patients with Stable Coronary Artery Disease) trial.

25 May 2010

DAPT Study expands into seven countries in the EU: HCRI

The Harvard Clinical Research Institute announced today that the DAPT Study has expanded into seven countries in the European Union. John Irving, MBChB, MRCP, M.D., consultant cardiologist at Ninewells Hospital in Dundee, United Kingdom, was the first European investigator to enroll patients into the study.

25 May 2010

Stentys receives CE Marking for drug-eluting stent

Stentys announced today that it has received CE Marking for its drug-eluting stent.

25 May 2010

Lack of discussion on resuming sex after heart attack associated with less sexual activity

Sexual activity declines in the year after heart attack for patients who don't get instructions from their doctors about when it's safe to resume sex, researchers reported at the American Heart Association's 11th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke.

21 May 2010

New research seeks customised treatment of cardiovascular diseases

The Centre for Cooperative Research in Biomaterials, CIC biomaGUNE, is involved in the research consortium of cvREMOD, which aims to move forward in the attainment of new diagnosis techniques for prevention and customised treatment of cardiovascular diseases in the upcoming four years.

21 May 2010

Arizona's smoking ban reduces hospital admissions for stroke, asthma and angina

Two University of Arizona researchers have studied the relationship between Arizona's 2007 law that bans smoking in public places and hospitalization rates for a range of ailments related to secondhand smoke exposure.

21 May 2010

New study shows preoperative statin therapy protects patients undergoing elective AAA repair

Preoperative statin therapy has a protective effect on patients undergoing elective abdominal aortic aneurysm repair that reduces risk and subsequent total hospital costs according to a new study from researchers at the East Carolina Heart Institute in Greenville, North Carolina.

20 May 2010

RegeneRx Biopharmaceuticals prices underwritten public offering at $0.41 per unit

RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company focused on the development of a novel therapeutic peptide, Thymosin beta 4, for tissue and organ protection, repair and regeneration in cardiovascular diseases, central nervous system injuries, ophthalmic indications and dermal wounds, announced the pricing of its previously announced underwritten public offering of 11,500,000 units of its securities at a public offering price of $0.41 per unit.

19 May 2010

Study reveals association between depression and coronary spasm

A study published in the current issue of Psychotherapy and Psychosomatics explores the relationship between depression and coronary artery spasm.

18 May 2010

China Sky One Medical first-quarter total revenues increase 16.4% to $28.9 million

China Sky One Medical, Inc., a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China, today announced record financial results for the first quarter of 2010. Management is working diligently to finalize the amended Annual Report on Form 10-K for 2009.

18 May 2010

Athersys presents data supporting MultiStem programs

Athersys, Inc. today presented data supporting its MultiStem® programs in cardiovascular disease, neurological disease and immune system modulation, and highlighted advancements in other areas, including progress in its drug development program in the area of obesity.

15 May 2010

Ambulance fees will deter emergency calls for help and risks lives: Study

Multiple data sources, including scientific survey data, medical studies and analyses of data in regions that have imposed ambulance fees, indicate that ambulance fees will discourage calls to emergency services for help, risking the health and safety of those experiencing medical emergencies.

14 May 2010

GRNCM1 do not cause cardiac arrhythmias after transplantation: Preclinical study

Geron Corporation today reported positive preclinical study data showing that GRNCM1, Geron's cardiomyocyte product derived from human embryonic stem cells, does not cause cardiac arrhythmias after transplantation into a model of chronic heart damage designed to test this potential safety concern.

14 May 2010

RegeneRx Biopharmaceuticals awarded $3M federal grant to develop heart attack drug

RegeneRx Biopharmaceuticals, Inc. announced today that it has been awarded a $3 million grant from the National Institutes of Health's National Heart, Lung and Blood Institute to support and accelerate the clinical development of its novel product candidate RGN-352, an injectable formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4, for patients who have suffered an acute myocardial infarction, or AMI, commonly known as a heart attack.

14 May 2010

CHD mortality rate in Ontario decreased by 35%: Study

From 1994 to 2005 in Ontario, Canada, there was a 35 percent decrease in the rate of deaths from coronary heart disease, with about half of this reduction associated with improvements in traditional CHD risk factors such as total cholesterol levels and systolic blood pressure, according to a study in the May 12 issue of JAMA.

12 May 2010

Sanofi-aventis commences multinational Phase IIIb PALLAS trial of Multaq in permanent AF patients

Sanofi-aventis announced today the initiation of a multinational, randomized double-blind Phase IIIb trial, PALLAS, to assess the potential clinical benefit of Multaq(R) (dronedarone) in over 10, 000 patients with permanent atrial fibrillation (AF) to reduce major adverse cardiovascular events. The announcement was made during Heart Rhythm 2010, the Heart Rhythm Society's 31st Annual Scientific Sessions.

12 May 2010

Everolimus-eluting stents more effective than paclitaxel-eluting stents

Results from the SPIRIT IV clinical trial, which were first presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2009 scientific symposium, were published today in the New England Journal of Medicine.

10 May 2010

Advances in combination adult stem cell treatment for acute myocardial infarction presented at SCAI

This week, TCA Cellular Therapy's Medical Director Gabriel Lasala, M.D. presents advances in a proprietary combination adult stem cell treatment for acute myocardial infarction at the Society for Cardiovascular Angiography and Interventions (SCAI) scientific conference in San Diego.

7 May 2010

Myocardial Infarction News and Research

Medtronic’s Resolute zotarolimus-eluting stent as effective as Xience V everolimus-eluting stent: Study

NEVO Sirolimus-eluting Coronary Stent demonstrates safety and efficacy outcomes at 12 months

St. Jude Medical initiates enrollment in FAME II trial for coronary artery disease

DAPT Study expands into seven countries in the EU: HCRI

Stentys receives CE Marking for drug-eluting stent

Lack of discussion on resuming sex after heart attack associated with less sexual activity

New research seeks customised treatment of cardiovascular diseases

Arizona's smoking ban reduces hospital admissions for stroke, asthma and angina

New study shows preoperative statin therapy protects patients undergoing elective AAA repair

RegeneRx Biopharmaceuticals prices underwritten public offering at $0.41 per unit

Study reveals association between depression and coronary spasm

China Sky One Medical first-quarter total revenues increase 16.4% to $28.9 million

Athersys presents data supporting MultiStem programs

Ambulance fees will deter emergency calls for help and risks lives: Study

GRNCM1 do not cause cardiac arrhythmias after transplantation: Preclinical study

RegeneRx Biopharmaceuticals awarded $3M federal grant to develop heart attack drug

CHD mortality rate in Ontario decreased by 35%: Study

Sanofi-aventis commences multinational Phase IIIb PALLAS trial of Multaq in permanent AF patients

Everolimus-eluting stents more effective than paclitaxel-eluting stents

Advances in combination adult stem cell treatment for acute myocardial infarction presented at SCAI

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence

Latest News